Hain Celestial (HAIN) Prelim. Q2 Numbers Light of Expectations

The Hain Celestial Group, Inc. (Nasdaq: HAIN) announced that the Company is scheduled to present at the ICR Conference on Tuesday, January 12, 2016 at 2:30 PM Eastern Time. A live audio webcast and a replay of the event will be available under the Investor Relations section of the Company's website at www.hain.com.

The Company provided second quarter fiscal year 2016 guidance projecting net sales in the range of $740.0 million to $760.0 million and earnings per diluted share of $0.53 to $0.56, reflecting the continuing strong performance of its Hain Pure Protein Corporation segment and its international businesses in constant currency offset by certain impacts relating to the United States segment including lower consumption and reductions in shipments and inventories at certain customers.

** The Street sees Q2 sales of $767 million and EPS of $0.57.

The Company is also updating its annual guidance. The Company's updated fiscal year 2016 guidance expectations are:

• Total net sales range of $2.90 billion to $3.04 billion, an increase of approximately 7% to 12% as compared to fiscal year 2015, which includes a forecasted unfavorable currency impact of approximately $75 million, and
• Earnings per diluted share range of $1.95 to $2.10, an increase of approximately 4% to 12% as compared to fiscal year 2015, which includes an estimated unfavorable currency impact of approximately $0.05 of earnings per diluted share.

** The Street sees FY16 revenue of $2.98 billion and EPS of $2.14.

Guidance is provided on a non-GAAP basis and excludes acquisition-related expenses, integration and restructuring charges, start-up costs, unrealized net foreign currency gains or losses, reserves for litigation matters and other non-recurring items, including any product recalls or market withdrawals, that have been or may be incurred during the Company's fiscal year 2016, which the Company will continue to identify as it reports its future financial results. Guidance excludes the impact of any future acquisitions.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• JPMorgan Starts Zensho Holdings (7550:JP) at Overweight
• Barclays Starts Sabra Healthcare REIT Inc. (SBRA) at Equalweight